Sign In
Buy ATHA
$6.61
+0 (+0%)
At Close: Apr 14, 2026
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
10:41am, Friday, 23'rd Aug 2024
Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
ATHA Energy signs LOI for joint venture on Canadian uranium projects
08:49am, Tuesday, 20'th Aug 2024
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced on Tuesday that it has signed a non-binding letter of intent (LOI) with Australian-listed Terra Uranium Ltd (ASX:T92) for a potential joint venture o
ATHA Energy Announces Proposed Option Agreements with Terra Uranium for Spire, Horizon, and Pasfield Projects
07:00am, Tuesday, 20'th Aug 2024
VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- ATHA Energy Corp. (TSXV: SASK) (FRA: X5U) (OTCQB: SASKF) (“ATHA”) is pleased to announce that it has entered into a non-binding lette
Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?
10:40am, Wednesday, 07'th Aug 2024
Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
04:05pm, Thursday, 01'st Aug 2024
Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease targeted for September 2024 Phase 2/3 LIFT-AD data to be
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
09:56am, Wednesday, 10'th Jul 2024
Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.
ATHA Energy expands uranium footprint at Angilak
08:51am, Wednesday, 10'th Jul 2024
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) said its 2024 exploration program at the Angilak project has successfully expanded the uranium mineralization footprint with a 100% hit rate. The company updat
HIGHLIGHTS: Angilak Project: The Angilak Project is host to the Lac 50 Uranium Deposit, which is one of the largest high-grade deposits outside of the Athabasca Basin, with a historical mineral resour
ATHA Energy director's machine learning innovation recognized by Future Explorer's Competition
09:31am, Monday, 17'th Jun 2024
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that its Director Geodata Drew Heasman, who leads its Digital Discovery team, has been awarded the top prize at the 2023/2024 Future Explorer's Compe
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
SEATTLE , June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al.
ATHA Energy commences 2024 Angilak diamond drilling program
09:53am, Monday, 03'rd Jun 2024
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has commenced Phase I of its 2024 Angilak Diamond Drilling Exploration Program at its Angilak Project in Nunavut. The program involves around 10,000 meters of
Athira Pharma to Participate in Upcoming June Conferences
07:00am, Wednesday, 29'th May 2024
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer's Disease on Track for Second Half of 2024 Management to Highlight Robust Pip
ATHA Energy enters option agreement with Riverboat Energy for Vista property in Athabasca Basin
09:56am, Tuesday, 28'th May 2024
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has signed an option agreement with Riverboat Energy Corporation, granting Riverboat the exclusive option to acquire a 70% interest in ATHA's Vista property in
